There were no statistically significant differences between the observed frequency and the expected number of FADS2 genotypes in the healthy control group (χ2 = 1.088, P = 0.297), the NAFLD group (χ2 = 0.001, P = 0.977), and the NAFLD+CAD group (χ2 = 0.797, P = 0.372), indicating that the observed frequency and expected number of FADS2 genotypes in each group were consistent. This evidence concerns the gene FADS2 and metabolic dysfunction-associated steatotic liver disease.